Legend Biotech (LEGN) Operating Margin (2022 - 2026)
Legend Biotech's (LEGN) quarterly Operating Margin came in at 16.32% in Q1 2026, up 1019.0% YoY from 1.46% in Q1 2025, and down 153.79% on a QoQ basis from 6.43% in Q4 2025.
Legend Biotech (LEGN) Operating Margin (2022 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 5 years of Operating Margin data on file, last reported at 16.32% in Q1 2026.
- Quarterly Operating Margin rose 1019.0% year-over-year to 16.32% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.64% (up 359.0% YoY) and the FY2025 annual result came in at 13.27%, up 3607.0% from the prior year.
- Operating Margin declined to 16.32% in Q1 2026, from 6.43% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 473.89% in Q3 2022 to a low of 43.92% in Q3 2024.
- A 5-year average of 132.71% and a median of 114.12% in 2025 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2023 — Operating Margin plunged 30574 bps — and 2025, when it jumped 3609 bps.
- Tracing LEGN's Operating Margin over 5 years: stood at 405.7% in 2022, then sank by 75 bps to 99.96% in 2023, then slumped by 143 bps to 42.52% in 2024, then soared by 85 bps to 6.43% in 2025, then sank by 154 bps to 16.32% in 2026.
- The last three Operating Margin figures came in at 16.32% (Q1 2026), 6.43% (Q4 2025), and 15.96% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 14.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.89% |
| Mar 31, 2026 | -16.32% |
| Dec 31, 2025 | -6.43% |
| Sep 30, 2025 | -15.96% |
| Jun 30, 2025 | 114.12% |
| Mar 31, 2025 | -26.51% |
| Dec 31, 2024 | -42.52% |
| Sep 30, 2024 | -43.92% |
| Jun 30, 2024 | 155.02% |
| Mar 31, 2024 | 189.15% |
| Dec 31, 2023 | 99.96% |
| Sep 30, 2023 | 183.82% |
| Jun 30, 2023 | 223.92% |
| Mar 31, 2023 | 296.72% |
| Dec 31, 2022 | 405.70% |
| Sep 30, 2022 | 473.89% |